Technical Analysis for IMUX - Immunic, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.27 | -7.97% | -0.11 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -7.97% | |
| Crossed Above 200 DMA | Bullish | -7.97% | |
| Pocket Pivot | Bullish Swing Setup | -7.97% | |
| Stochastic Reached Overbought | Strength | -7.97% | |
| Outside Day | Range Expansion | -7.97% |
| Alert | Time |
|---|---|
| Fell Below 20 DMA | about 9 hours ago |
| Fell Below 10 DMA | about 9 hours ago |
| 20 DMA Support | about 10 hours ago |
| Down 1 ATR | about 11 hours ago |
| 60 Minute Opening Range Breakdown | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Immunic, Inc. Description
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Clinical Development Autoimmune Disease Psoriasis Multiple Sclerosis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Inflammatory And Autoimmune Diseases Mayo Clinic Primary Sclerosing Cholangitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.11 |
| 52 Week Low | 0.9451 |
| Average Volume | 391,779 |
| 200-Day Moving Average | 1.37 |
| 50-Day Moving Average | 1.33 |
| 20-Day Moving Average | 1.29 |
| 10-Day Moving Average | 1.30 |
| Average True Range | 0.09 |
| RSI (14) | 47.64 |
| ADX | 12.48 |
| +DI | 21.80 |
| -DI | 14.81 |
| Chandelier Exit (Long, 3 ATRs) | 1.20 |
| Chandelier Exit (Short, 3 ATRs) | 1.43 |
| Upper Bollinger Bands | 1.42 |
| Lower Bollinger Band | 1.15 |
| Percent B (%b) | 0.43 |
| BandWidth | 21.06 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0101 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.45 | ||||
| Resistance 3 (R3) | 1.47 | 1.43 | 1.42 | ||
| Resistance 2 (R2) | 1.43 | 1.38 | 1.42 | 1.41 | |
| Resistance 1 (R1) | 1.35 | 1.36 | 1.33 | 1.33 | 1.40 |
| Pivot Point | 1.31 | 1.31 | 1.30 | 1.30 | 1.31 |
| Support 1 (S1) | 1.23 | 1.26 | 1.21 | 1.21 | 1.14 |
| Support 2 (S2) | 1.19 | 1.24 | 1.18 | 1.13 | |
| Support 3 (S3) | 1.11 | 1.19 | 1.12 | ||
| Support 4 (S4) | 1.09 |
